secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001093557-25-000264
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom appoints Dr. Euan Ashley to board; board size expanded to 11 in 2026
---------------------------------------------------------------------------

- Appointed Euan Ashley, M.D., to Board effective Oct 24, 2025; board size increased to 10 then to 11 effective Jan 1, 2026.
- Ashley chairs Stanford Dept. of Medicine, co-founded 7 biotech firms, brings clinical and AI/digital health expertise.
- Received initial RSU grant of $500k vesting over 3 years; eligible for annual director equity grant of $345k.
- Appointed to Nominating and Governance Committee and Technology Committee; Kyle Malady steps down from Nominating but remains Tech chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000264/0001093557-25-000264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355725000264/dxcm-20251024.htm
  HTML page:      https://secwatch.observer/filing/0001093557-25-000264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer